Cargando…

Tesaglitazar ameliorates non-alcoholic fatty liver disease and atherosclerosis development in diabetic low-density lipoprotein receptor-deficient mice

Previous research has demonstrated that the dual PPARα/γ agonist tesaglitazar reduces atherosclerosis in a mouse model of hyperlipidemia by reducing both lipid content and inflammation in the aorta. However, much of the underlying mechanism of tesaglitazar in non-alcoholic fatty liver disease (NAFLD...

Descripción completa

Detalles Bibliográficos
Autores principales:	ZHANG, BU-CHUN, LI, WEI-MING, LI, XIAN-KAI, ZHU, MENG-YUN, CHE, WEN-LIANG, XU, YA-WEI
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2012
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494130/ https://www.ncbi.nlm.nih.gov/pubmed/23226761 http://dx.doi.org/10.3892/etm.2012.713

Ejemplares similares

Salidroside Decreases Atherosclerotic Plaque Formation in Low-Density Lipoprotein Receptor-Deficient Mice
por: Zhang, Bu-Chun, et al.
Publicado: (2012)

Low-density lipoprotein particles in atherosclerosis
por: Qiao, Ya-Nan, et al.
Publicado: (2022)

GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice
por: Quarta, Carmelo, et al.
Publicado: (2022)

Folic acid delays development of atherosclerosis in low‐density lipoprotein receptor‐deficient mice
por: Pan, Sunlei, et al.
Publicado: (2018)

Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis
por: Lee, Chih-Kuo, et al.
Publicado: (2021)

Myricetin ameliorates atherosclerosis in the low-density-lipoprotein receptor knockout mice by suppression of cholesterol accumulation in macrophage foam cells
por: Meng, Zhe, et al.
Publicado: (2019)

High-density lipoproteins and non-alcoholic fatty liver disease
por: Hoekstra, Menno, et al.
Publicado: (2023)

The PPARα/γ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat
por: Wallenius, Kristina, et al.
Publicado: (2013)

Myeloid β-Catenin Deficiency Exacerbates Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice
por: Wang, Fang, et al.
Publicado: (2018)

Hepatic paraoxonase 1 ameliorates dysfunctional high-density lipoprotein and atherosclerosis in scavenger receptor class B type I deficient mice
por: Zhao, Xiao-Jie, et al.
Publicado: (2021)

Probucol alleviates atherosclerosis and improves high density lipoprotein function
por: Zhong, Jian-Kai, et al.
Publicado: (2011)

Low-Density Lipoprotein Cholesterol, Structural Atherosclerosis, and Functional Atherosclerosis in Older Japanese
por: Shimizu, Yuji, et al.
Publicado: (2022)

Dietary-Induced Elevations of Triglyceride-Rich Lipoproteins Promote Atherosclerosis in the Low-Density Lipoprotein Receptor Knockout Syrian Golden Hamster
por: Lin, Xiao, et al.
Publicado: (2021)

High density lipoproteins and atherosclerosis: emerging aspects
por: Sala, Federica, et al.
Publicado: (2012)

High density lipoprotein mimicking nanoparticles for atherosclerosis
por: Chen, Jun, et al.
Publicado: (2020)

Relationship between Concentration Difference of Different Density Lipoproteins and Shear Stress in Atherosclerosis
por: Meng, Wei, et al.
Publicado: (2012)

Cysteamine Decreases Low‐Density Lipoprotein Oxidation, Causes Regression of Atherosclerosis, and Improves Liver and Muscle Function in Low‐Density Lipoprotein Receptor–Deficient Mice
por: Ahmad, Feroz, et al.
Publicado: (2021)

HIV Protein Tat Induces Macrophage Dysfunction and Atherosclerosis Development in Low-Density Lipoprotein Receptor-Deficient Mice
por: Meng, Zhaojie, et al.
Publicado: (2022)

Oxidized low density lipoprotein, stem cells, and atherosclerosis
por: Yang, Hui, et al.
Publicado: (2012)

High-Density Lipoprotein, Lecithin: Cholesterol Acyltransferase, and Atherosclerosis
por: Ossoli, Alice, et al.
Publicado: (2016)

Rosiglitazone attenuates atherosclerosis and increases high-density lipoprotein function in atherosclerotic rabbits
por: LI, CHEN, et al.
Publicado: (2015)

The Role of Oxidized Low-Density Lipoproteins in Atherosclerosis: The Myths and the Facts
por: Maiolino, Giuseppe, et al.
Publicado: (2013)

Mechanistic Insights into the Oxidized Low-Density Lipoprotein-Induced Atherosclerosis
por: Khatana, Chainika, et al.
Publicado: (2020)

Ghrelin Receptor Deficiency does not Affect Diet-Induced Atherosclerosis in Low-Density Lipoprotein Receptor-Null Mice
por: Habegger, Kirk M., et al.
Publicado: (2011)

Atherosclerosis and cardiac function assessment in low-density lipoprotein receptor-deficient mice undergoing body weight cycling
por: McMillen, T S, et al.
Publicado: (2013)

Spontaneous severe hypercholesterolemia and atherosclerosis lesions in rabbits with deficiency of low-density lipoprotein receptor (LDLR) on exon 7
por: Lu, Rui, et al.
Publicado: (2018)

Proteomic characterization of high-density lipoprotein particles in patients with non-alcoholic fatty liver disease
por: Rao, Prahlad K., et al.
Publicado: (2018)

Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6) Is a Novel Nutritional Therapeutic Target for Hyperlipidemia, Non-Alcoholic Fatty Liver Disease, and Atherosclerosis
por: Go, Gwang-woong
Publicado: (2015)

The Potential Role of Electronegative High-Density Lipoprotein H5 Subfraction in RA-Related Atherosclerosis
por: Chang, Ching-Kun, et al.
Publicado: (2021)

Amelioration of atherosclerosis in apolipoprotein E-deficient mice by combined RNA interference of lipoprotein-associated phospholipase A(2) and YKL-40
por: Zhang, Hui, et al.
Publicado: (2018)

Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis
por: Hermansson, Andreas, et al.
Publicado: (2010)

Utility of Atherosclerosis Imaging in the Evaluation of High-Density Lipoprotein–Raising Therapies
por: Duivenvoorden, Raphaël, et al.
Publicado: (2011)

Porphyromonas gingivalis accelerates atherosclerosis through oxidation of high-density lipoprotein
por: Kim, Hyun-Joo, et al.
Publicado: (2018)

Significance of Triglyceride-to-High-Density Lipoprotein Cholesterol Ratio in Children with Non-Alcoholic Fatty Liver Disease
por: Kim, Hyun Jin
Publicado: (2023)

Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis
por: Zhang, Bai-Hui, et al.
Publicado: (2022)

In vivo liposomal delivery of PPARα/γ dual agonist tesaglitazar in a model of obesity enriches macrophage targeting and limits liver and kidney drug effects
por: Osinski, Victoria, et al.
Publicado: (2020)

Neutrophil-Derived Myeloperoxidase Aggravates Non-Alcoholic Steatohepatitis in Low-Density Lipoprotein Receptor-Deficient Mice
por: Rensen, Sander S., et al.
Publicado: (2012)

Lipids and Lipoproteins in Atherosclerosis
por: Chroni, Angeliki, et al.
Publicado: (2011)

Lipids and Lipoproteins in Atherosclerosis
por: Bezsonov, Evgeny, et al.
Publicado: (2023)

The Alcohol–High-Density Lipoprotein Athero-Protective Axis
por: Rosales, Corina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ofgqvms586s8uv7lhigdhejdh5